Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
GvHD: early-phase trial registry
3 of 7 indexed GvHD trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · 3 currently recruiting · #2,497 of 28,707 conditions by registered trial count
GvHD: 7 US clinical trials tracked, 3 recruiting.
GvHD is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Neovii Biotech, running 1 of these trials.
Enrollment posture brief
Registry condition gvhd
OPEN 3 | RECR 43% | LATE 1 | EARLY 5 | RANK #2497 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adrenoleukodystrophy (43% recruiting · 7 trials)
GvHD lists 3 open slots (43% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for GvHD on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
GvHD is recruiting below its size-band peers.
3 of 7 indexed trials (42.9%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of GvHD trials is spread across many organizations.
Neovii Biotech accounts for 1 of 7 trials (14.3%). 7 distinct sponsors appear on at least one study for this condition label.
-
Most GvHD trials plan to enrol fewer than 100 people.
Median target enrolment is 43 among the 7 trials that report a genuine target (sentinel values excluded). 6 of those (85.7%) plan for fewer than 100 participants.
-
GvHD research is mostly interventional.
7 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
7 total, page 1 of 1
Diagnostic Refinement and Educational Approaches in Managing Bone Marrow Transplantation
Scripps Health
NCT06590285
A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant
Memorial Sloan Kettering Cancer Center
NCT05675930
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Tr1X
NCT06462365
Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)
Neovii Biotech
NCT01295710
Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation
Dimitrios Tzachanis, MD PhD
NCT03680092
A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression
H. Lee Moffitt Cancer Center and Research Institute
NCT02891603
A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD
John Levine
NCT03459040
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 3 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on GvHD records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on GvHD trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this GvHD page
7 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 GvHD trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Neovii Biotech sponsors the most GvHD trials on record, review their full trial history before evaluating a specific study. See Neovii Biotech's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This GvHD condition card totals 7 registered trials; most-linked intervention Tacrolimus; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.